Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators

使用患者导航仪增强羟基脲在镰状细胞病中的应用

基本信息

  • 批准号:
    8268195
  • 负责人:
  • 金额:
    $ 65.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-15 至 2017-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Large percentage of patients may not be in SCD specialty care, and may face barriers to care. For adults, not having specialty care may be fatal, because specialists may prescribe Hydroxyurea (HU), the first and only FDA approved remittive drug for SCD. Additional barriers to HU include physician fears or misconceptions about its use, inconsistent determination of HU eligibility and inconsistent dose escalation, and patient failure to take HU, due to ignorance or mistrust of relative benefit sand harms, inconvenience associated with therapy, or poor medication access. To overcome these barriers, the state of Virginia, including the Virginia Department of Health and two academic medical centers, plans a two phase demonstration, first of improvement in the percentage of adults with SCD who are in SCD specialty care (PhaseI), then of improvement in adherence to HU of eligible SCD adults (PhaseII). Both phases will use existing academic SCD providers, and an innovative, multimodal strategy, featuring specially trained SCD patient navigators (PNs), that addresses barriers to care and to HU use. In Phase I we will demonstrate the feasibility of utilizing PNs to overcome patient access barriers to SCD care. In Phase II we will test the efficacy of PNs for overcoming barriers to acceptance of and adherence with Hu therapy. Patients will be randomized to a PN or usual care arm. Providers will implement NIH guidelines for HU eligibility and prescribing in both arms. The primary outcome variable for Phase I will be the percentage of enrollees who in the subsequent three months achieve a visit with a specialty SCD provider. The primary outcome for Phase II will be improvement in the HbF level at 1 year post randomization. Secondary outcomes will include: four measures of adherence to HU; percent of patients achieving either maximum tolerated dose, a clinical endpoint, or maximum dose; ED and hospital visits; mean corpuscular volume; total hemoglobin; white blood cell count; reticulocyte count; and quality of life. Co variates in PhaseII will include: patient demographics; genotype; social support; SCD associated pain conditions; mental health status and alcohol use; and coping measures. This project will be critically important and impactful by demonstrating the feasibility of a statewide community based strategy to assist vulnerable SCD adults in obtaining SCD specialty care and likely prolonging life, a model that other states could adopt. PUBLIC HEALTH RELEVANCE: To overcome barriers to hydroxyurea (HU) among adults with sickle cell disease (SCD), the state of Virginia, including the Virginia Department of Health and two academic medical centers, plans a two- phase demonstration, first of improvement in the percentage of adults with SCD who are in SCD specialty care (Phase I), then of improvement in adherence to HU of eligible SCD adults (Phase II). This project will be critically important and impactful by demonstrating the feasibility of a statewide community-based strategy to assist vulnerable SCD adults in obtaining SCD specialty care and likely prolonging life, a model that other states could adopt.
描述(由申请人提供):大部分患者可能未接受SCD专科护理,可能面临护理障碍。对于成年人来说,没有专业护理可能是致命的,因为专家可能会开羟基脲(HU),这是FDA批准的第一种也是唯一一种用于SCD的缓解药物。HU的其他障碍包括医生对其使用的恐惧或误解,HU合格性的不一致确定和不一致的剂量递增,以及由于对相对获益和危害的无知或不信任,与治疗相关的不便或药物可及性差而导致的患者未能服用HU。为了克服这些障碍,弗吉尼亚州,包括弗吉尼亚州卫生部和两个学术医疗中心,计划进行两个阶段的示范,首先是改善SCD专科护理中SCD成人的百分比(第一阶段),然后是改善符合条件的SCD成人的HU(第二阶段)。这两个阶段都将使用现有的学术SCD提供者,以及一种创新的多模式战略,包括经过专门培训的SCD患者导航员(PN),以解决护理和HU使用的障碍。在第一阶段,我们将证明利用PN克服SCD治疗患者获取障碍的可行性。在第二阶段,我们将测试PNs克服接受和坚持Hu治疗的障碍的疗效。患者将被随机分配到PN或常规护理组。提供者将执行NIH指南,以确定两组的HU资格和处方。第一阶段的主要结局变量是在随后三个月内实现专科SCD提供者访视的入组者百分比。II期的主要结局是随机化后1年时HbF水平的改善。次要结局将包括:HU依从性的四个指标;达到最大耐受剂量、临床终点或最大剂量的患者百分比;艾德和医院访视;平均红细胞体积;总血红蛋白;白色血细胞计数;网织红细胞计数;和生活质量。第II阶段的协变量包括:患者人口统计学;基因型;社会支持; SCD相关疼痛状况;心理健康状况和酒精使用;以及应对措施。该项目将通过展示全州范围内基于社区的战略的可行性来发挥至关重要和影响力,以帮助弱势SCD成年人获得SCD专科护理并可能延长生命,这是其他州可以采用的模式。 公共卫生关系:为了克服患有镰状细胞病(SCD)的成年人中的羟基脲(HU)障碍,弗吉尼亚州,包括弗吉尼亚州卫生部和两个学术医学中心,计划进行两阶段论证,首先是改善患有SCD的成年人中接受SCD专科护理的百分比(第I阶段),然后是改善符合条件的SCD成年人对HU的依从性(第II阶段)。 该项目将通过展示全州范围内以社区为基础的战略的可行性,以帮助弱势SCD成年人获得SCD专科护理并可能延长生命,这是其他州可以采用的模式,具有至关重要的影响力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wally R Smith其他文献

Incidence, Prevalence, and Disease Management Impactability of High Utilization in an Adult Sickle Cell Medical Home
  • DOI:
    10.1182/blood-2023-187621
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Wally R Smith;Daniel Sop;Yue May Zhang;Benjamin Jaworowski;Shirley Johnson
  • 通讯作者:
    Shirley Johnson
Towards an Implicit Measure of Patient Engagement in Sickle Cell Disease: Relationships between Implicit Measures of Engagement and Previous Childhood Trauma Among Adolescents and Young Adults
  • DOI:
    10.1182/blood-2023-187552
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Haylee Hartzog;Shirley Johnson;Rachel Walls;Yue May Zhang;Daniel Sop;Wally R Smith
  • 通讯作者:
    Wally R Smith
Oxycodone Produces Antinociception, but Worsens Functional Behaviors, in Humanized Sickle Cell Disease Mice
  • DOI:
    10.1182/blood-2022-162675
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Kennedy N Goldsborough;Molly Sonenklar;Kalpna Gupta;M Imad Damaj;Wally R Smith;Joyce Lloyd;Aron Lichtman
  • 通讯作者:
    Aron Lichtman
A Patient-Centric Approach to Sickle Cell Disease Clinical Trials: Integrating Patient Perspectives in the RISE UP Phase 2/3 Trial of Mitapivat for Informed Protocol Design and Associated Patient Community Benefit
  • DOI:
    10.1182/blood-2023-186710
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Charles R. Jonassaint;Blaze Armon Eppinger;Dominique Friend;Golie Lorenzo Green;Mia Robinson;Teonna Woolford;DeMitrious Wyant;Janie Davis;Abdulafeez Oluyadi;Ahmar U Zaidi;Holly John;Wally R Smith
  • 通讯作者:
    Wally R Smith
“It Was Bootstrap All the Way”: Exploring the Barriers and Facilitators to the Development of Non-Hematology Sickle Cell Disease Experts in the United States
  • DOI:
    10.1182/blood-2024-203728
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Francis W Coyne;Deirdra R Terrell;Valerie Lang;Ashley M Jenkins;Allison A. King;Wally R Smith
  • 通讯作者:
    Wally R Smith

Wally R Smith的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wally R Smith', 18)}}的其他基金

Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators
使用患者导航仪增强羟基脲在镰状细胞病中的应用
  • 批准号:
    8904700
  • 财政年份:
    2012
  • 资助金额:
    $ 65.04万
  • 项目类别:
Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators
使用患者导航仪增强羟基脲在镰状细胞病中的应用
  • 批准号:
    9116288
  • 财政年份:
    2012
  • 资助金额:
    $ 65.04万
  • 项目类别:
Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators
使用患者导航仪增强羟基脲在镰状细胞病中的应用
  • 批准号:
    8698808
  • 财政年份:
    2012
  • 资助金额:
    $ 65.04万
  • 项目类别:
Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators
使用患者导航仪增强羟基脲在镰状细胞病中的应用
  • 批准号:
    8529610
  • 财政年份:
    2012
  • 资助金额:
    $ 65.04万
  • 项目类别:
Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators
使用患者导航仪增强羟基脲在镰状细胞病中的应用
  • 批准号:
    9564278
  • 财政年份:
    2012
  • 资助金额:
    $ 65.04万
  • 项目类别:
Comparative Effectiveness of Virginia Coordinated Care versus the Traditional Saf
弗吉尼亚协调护理与传统 SAF 的效果比较
  • 批准号:
    8055657
  • 财政年份:
    2010
  • 资助金额:
    $ 65.04万
  • 项目类别:
MORPHINE PHARMACOKINETICS AND PHARMACODYNAMICS IN SICKLE CELL DISEASE
吗啡在镰状细胞病中的药代动力学和药效学
  • 批准号:
    8166575
  • 财政年份:
    2009
  • 资助金额:
    $ 65.04万
  • 项目类别:
Virginia Basic and Translational Research Program
弗吉尼亚基础和转化研究计划
  • 批准号:
    7916725
  • 财政年份:
    2008
  • 资助金额:
    $ 65.04万
  • 项目类别:
Virginia Basic and Translational Research Program
弗吉尼亚基础和转化研究计划
  • 批准号:
    7640493
  • 财政年份:
    2008
  • 资助金额:
    $ 65.04万
  • 项目类别:
Virginia Commonwealth University Sickle Cell Disease
弗吉尼亚联邦大学镰状细胞病
  • 批准号:
    7060251
  • 财政年份:
    2006
  • 资助金额:
    $ 65.04万
  • 项目类别:

相似海外基金

Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 65.04万
  • 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
  • 批准号:
    10738120
  • 财政年份:
    2023
  • 资助金额:
    $ 65.04万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10526768
  • 财政年份:
    2022
  • 资助金额:
    $ 65.04万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10701072
  • 财政年份:
    2022
  • 资助金额:
    $ 65.04万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10679092
  • 财政年份:
    2021
  • 资助金额:
    $ 65.04万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10432133
  • 财政年份:
    2021
  • 资助金额:
    $ 65.04万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10327065
  • 财政年份:
    2021
  • 资助金额:
    $ 65.04万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10377366
  • 财政年份:
    2019
  • 资助金额:
    $ 65.04万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10574496
  • 财政年份:
    2019
  • 资助金额:
    $ 65.04万
  • 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
  • 批准号:
    9403567
  • 财政年份:
    2017
  • 资助金额:
    $ 65.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了